There is an ongoing need to provide clinical updates in diabetes on an annual basis; therefore this course is designed to fulfill a need for diabetes education in the primary care setting. Data sources on the prevalence of diabetes in the US as well as interest expressed at the local chapter level will be used to determine the targeted locations throughout the US in which to hold this education.

The current epidemic of T2DM and the recognition that achieving specific glycemic goals can substantially reduce morbidity have made the effective treatment of hyperglycemia a top priority. The mainstays of therapy, namely lifestyle modification and pharmacological therapies such as oral antidiabetes drugs (OADs) and insulin, have proven safe and effective when used aggressively for the treatment of T2DM.

The management of patients with T2DM is continuously evolving as a result of the development and release of new medications, increased experience with marketed agents, changing treatment algorithms, as well as results of new, and potentially, controversial findings from the published medical literature. This year has also seen an addition to the way diabetes can be diagnosed.

This practical course is designed around case presentations to bring and simplify the latest knowledge in the management of diabetes, as well as prediabetes, and the influence that obesity plays on both conditions, to physicians and other practitioners who are interested in the care of such patients.

Specific areas to be covered include: the impact of obesity on the prevalence of diabetes, T2DM pathophysiology, diagnosis, and treatment goals (not only glucose goals, but lipid and blood pressure goals as well), oral and injectable based therapies to including the role of amylin agonists, incretin-based therapies, and other novel agents. The important role of insulin therapy as a tool for primary care physicians will also be discussed. Information about patient management and monitoring, the role of the patient in self-management, and the need for multidisciplinary efforts to improve patient outcomes will be shared. At the conclusion of the program, the faculty present case studies to help implementation of the knowledge into clinical practice.

After participating in the continuing education program, participants will have an improved ability to:

• Describe the main aspects of diabetes pathophysiology and which classes of therapeutic agents target which defects.
• Explain to patients that type 2 diabetes is a progressive disease with changing therapeutic needs.
• Discuss the role of combination therapy and when it should be initiated based on A1C goals.
• Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C lowering needed, patient specific concerns, adverse effects, comorbidities, and contraindications.
• State the modes of action and clinical potential of amylin agonists, incretin-based therapies, the bile acid sequestrant colesevelam, and bromocriptione in the management of patients with type 2 diabetes.
• Differentiate new treatment strategies with respect to A1C lowering potential, route of administration, effects on weight and/or CV risk factors, and whether or not they can be used as part of mono- or combination therapy strategies.
• Differentiate human and insulin analogs from each other in terms of pharmacokinetics, predictability, incidence of hypoglycemia or weight gain, and patient administration.
• Describe ways to introduce insulin to patients that are candidates for this therapy
• Incorporate patient education in self-management in treatment approaches.
• Understand the implications of recent clinical trials and meta-analyses on clinical practice decisions.
• Develop strategies to involve other healthcare professionals to support the care of patents with type 2 diabetes.
• Apply knowledge from this program to daily patient care practices to improve the outcome of patients with type 2 diabetes

Primary care providers including MDs, DOs, NPs, PAs, RNs, CDEs, Pharmacists and other interested health care providers.

George Grunberger, MD, FACP, FACE
Local Program Chair
Chairman, Grunberger Diabetes Institute
Clinical Professor, Internal Medicine and Molecular Medicine & Genetics
Wayne State University School of Medicine
Detroit, MI

Gary W. Edelson, MD
Associated Endocrinologists, PC
Clinical Associate Professor of Medicine
Wayne State University
Detroit, MI
Professor, Oakland University
William Beaumont School of Medicine
Rochester, MI

Lowell R. Schmeltz, MD
Associated Endocrinologists, PC
Chief, Division of Endocrinology & Metabolism
Detroit Medical Center, Huron Valley-Sinai Hospital
Commerce Township, MI
Assistant Professor, Oakland University
William Beaumont School of Medicine
Rochester, MI

Kirit Tolia, MD, FACE
Medical Director and Chief of Endocrinology
Joslin Diabetes Center at Providence Hospital
Southfield, MI
Associate Clinical Professor of Medicine
Wayne State University
Detroit, MI

The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this live educational activity for a maximum of 4.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity, Diabetes Day for Primary Care Physicians, with a beginning date of September 11, 2010, has been reviewed and is acceptable for up to 4.50 Prescribed credits by the American Academy of Family Physicians.

®	Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Postgraduate Institute for Medicine designates this continuing education activity for 4.5 contact hour(s) (0.45 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - 809-999-10-097-L01-P)

Type of Activity: Knowledge-Based

This educational activity for 4.5 contact hours is provided by Postgraduate Institute for Medicine.

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Postgraduate Institute for Medicine is approved by the California Board of Registered Nursing, Provider Number 13485 for 5.4 contact hours.

There is no fee for this educational activity.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be mailed to you within three weeks.

AACE would like to acknowledge the following organizations and companies that have provided or pledged support for this educational activity.

Amylin Pharmaceuticals, Inc, and Lilly USA, LLC

Boehringer Ingelheim Pharmaceuticals, Inc.

Bristol-Myers Squibb and AstraZeneca Pharmaceuticals LP, Alliance Partners

Daiichi Sankyo, Inc.

Novo Nordisk Inc.

sanofi-aventis U.S. Inc.

For exhibit information, please contact:

• Kathy Harper
  Chapters Coordinator
  245 Riverside Avenue, Suite 200
  Jacksonville, FL 32202
  Phone : 904-353-7878, ext. 121
  FAX: 904-353-8185
  Email: kharper@aace.com